2003
DOI: 10.2165/00002512-200320100-00006
|View full text |Cite
|
Sign up to set email alerts
|

A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer???s Disease

Abstract: Significant advantages were found in the treatment response to galantamine (versus donepezil) on cognition as measured by response rates on the MMSE and ADAS-cog/11.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

5
118
3
5

Year Published

2004
2004
2018
2018

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 185 publications
(131 citation statements)
references
References 43 publications
5
118
3
5
Order By: Relevance
“…7 Clinical studies have shown that ChEI therapy, both in the earlier stages and in more advanced AD, provides symptomatic benefits 8 -20 and eases caregiver burden. 18,21,22 Similar benefits on symptoms were seen in an observational study reflecting everyday clinical practice. 23 Although AD is a progressive disease, ChEI therapy has also been associated with a slowing of the decline in global function compared with untreated patients.…”
Section: Introductionsupporting
confidence: 59%
“…7 Clinical studies have shown that ChEI therapy, both in the earlier stages and in more advanced AD, provides symptomatic benefits 8 -20 and eases caregiver burden. 18,21,22 Similar benefits on symptoms were seen in an observational study reflecting everyday clinical practice. 23 Although AD is a progressive disease, ChEI therapy has also been associated with a slowing of the decline in global function compared with untreated patients.…”
Section: Introductionsupporting
confidence: 59%
“…One trial 192 that did not meet the inclusion criteria as it did not state that the population was mild to moderately severe AD and the MMSE was 9-18, which fell just outside of the 10-26 range, did undertake a subgroup analysis on those with an MMSE of 12-18. Although this study was technically an exclusion from the review, because of the difficulties with defining disease severity noted above, the subgroup analysis has been summarised here.…”
Section: Participant Characteristicsmentioning
confidence: 99%
“…The anticholinergic scopolamine induces sleep and episodic memory loss (Curran et al 1998), and thus the use of antimuscarinic medication in disorders such as PD, itself associated with sleep disturbances, may promote specific memory impairments. Cholinesterase inhibitors (ChEI) improve sleep and cognitive function in AD (Grace et al 2000;Wilcock et al 2003). In non-demented subjects, improvements in memory with ChEI are reported to relate to increased REM (Schredl et al 2001) but with the side effect of insomnia ( Jacobsen & Comas-Diaz 1999).…”
Section: New Perspectives On Sleep Disturbances and Memory In Human Pmentioning
confidence: 99%